Abstract
Introduction
Standard multidrug-resistant tuberculosis (MDR-TB) treatment is lengthy, toxic, and insufficiently effective. New drugs and a shorter treatment regimen (SCR) are now recommended. However, patient and health-care worker (HCW) perspectives regarding the SCR are unknown. We aimed to determine the views and experiences of patients with MDR-TB and HCW regarding the SCR in Karakalpakstan, Uzbekistan.
Methods
In a qualitative study, we conducted 48 in-depth interviews with 24 people with MDR-TB and 20 HCW, purposively recruited to include those with a range of treatment-taking experiences and employment positions. Data were analysed thematically using Nvivo 12, to identify emergent patterns, concepts, and categories. Principles of grounded theory were drawn upon to generate findings inductively from participants’ accounts.
Results
All patients viewed the SCR favourably. The SCR was seen as enabling an expedited return to work, studies, and “normality”. This reduced the burden of treatment and difficulties with treatment fatigue. The SCR appeared to improve mental health, ease difficulties with TB-related stigma, and foster improved adherence. While patients wanted shorter treatment, it was also important that treatment be tolerable and effective. However, HCW doubted the appropriateness and effectiveness of the SCR, which influenced their confidence in prescribing the regimen.
Conclusion
The SCR was said to benefit treatment completion and patients’ lives. HCW concerns about SCR appropriateness and effectiveness may influence who receives the regimen. These are important considerations for SCR implementation and MDR-TB treatment developments, and dissonance between patient and HCW perspectives must be addressed for successful implementation of shorter regimens in the future.
Publisher
Public Library of Science (PLoS)
Reference30 articles.
1. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe;C Lange;Am J Respir Crit Care Med,2016
2. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives;E Pontali;Eur Respir Rev,2019
3. Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings;G Sotgiu;Int J Infect Dis IJID Off Publ Int Soc Infect Dis,2017
4. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis;DR Silva;J Bras Pneumol,2018
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献